Tag: RSV
-
Beyfortus (Nirsevimab) Arrives in Malaysia to Shield Infants from RSV
Malaysia Approves Beyfortus (Nirsevimab) to Guard Infants Against RSV In a move welcomed by pediatric health advocates, Beyfortus (Nirsevimab), the preventive monoclonal antibody developed by Sanofi and AstraZeneca, has been approved by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants. The approval…
-
Now is the Time to Protect Babies from RSV: Practical Steps for Parents
RSV: Why This Season Demands Extra Vigilance for Babies Respiratory syncytial virus (RSV) is a common winter illness that can affect people of all ages, but infants—especially newborns and those with underlying health issues—are at higher risk for severe disease. Pediatricians, including Kristin Barrett of Cleveland Clinic Children’s, stress that protecting infants from RSV isn’t…
-
Now Is the Time to Protect Babies From RSV: Practical Guidance for Parents
RSV: A Common Threat to Baby Health Respiratory syncytial virus (RSV) is a pervasive infection in communities, especially common in fall and winter. While many healthy adults recover quickly, RSV can be serious for babies, particularly those born prematurely or with underlying health issues. Pediatric experts, including Kristin Barrett from Cleveland Clinic Children’s, emphasize that…
-
Protect Babies from RSV: Essential Prevention Tips
Why RSV Matters for Babies RSV, or respiratory syncytial virus, is a common respiratory infection that can be especially serious for infants. Pediatric experts note that while RSV is widespread in communities, certain babies are more vulnerable to severe illness. Dr. Kristin Barrett, a pediatrician at Cleveland Clinic Children’s, emphasizes the importance of protecting newborns…
-
BC’s Respiratory Illness Season: What This Year Looks Like So Far
What the early numbers suggest British Columbia is several weeks into its fall vaccination campaign, and early indicators point to a respiratory illness season that could test hospitals, workplaces, and households alike. Health authorities are watching trends for influenza, respiratory syncytial virus (RSV), and COVID-19, alongside other common cold- and flu-like illnesses. While precise counts…
-
How BC’s Respiratory Illness Season Is Shaping Up This Year
What this respiratory illness season might look like in British Columbia As fall settles in, British Columbians are again navigating a familiar mix: sniffles, coughs, and the familiar chorus of notices about respiratory illnesses. Health officials emphasize that while seasonality is predictable, the exact mix of influenza, RSV, and other respiratory pathogens can vary from…
-
Monoclonal Antibodies Shield Infants from RSV: A New Era of Protection
Understanding RSV and the Vulnerable Population Respiratory syncytial virus (RSV) is a common winter respiratory infection that typically presents as a cold-like illness in healthy individuals. Yet, for young infants—especially those under six months—the elderly, and children with certain health conditions, RSV can lead to serious complications requiring hospitalization. In recent years, scientists and clinicians…
-
Monoclonal Antibodies Shield Infants from RSV: A New Line of Defense
What is RSV and why is it a concern for infants? Respiratory syncytial virus (RSV) is a common winter illness that typically causes cold-like symptoms. For many healthy adults, it is a mild inconvenience, but for young infants—especially those under six months—or older adults, RSV can lead to serious breathing difficulties and hospital stays. The…
-
Monoclonal Antibodies Shield Infants from RSV
RSV in Infants: A Critical Early Challenge Respiratory syncytial virus (RSV) is a common wintertime pathogen that most healthy adults weather with mild cold-like symptoms. For infants, especially those under six months, RSV can lead to bronchiolitis and pneumonia, sometimes necessitating hospital care. While vaccination strategies for other age groups exist, protecting newborns and very…
-
Monoclonal Antibody Protects Children from RSV: Real-World Evidence
Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…